You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Selectively Absorbable Surgical Mesh for Hernia Repair

    SBC: POLY-MED, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Hernia repair is one of the most frequently performed surgical operations in the United States with approximately 800,000 procedures performed annually. The vast majority of these repairs employ a tension- free repairtechnique which involves the use of synthetic surgical meshes. Existing mesh technology is designed to be of high strength to produce a perceive ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Biomarker Matrix for Genotoxicity Mode of Action

    SBC: Litron Laboratories Ltd            Topic: NIEHS

    DESCRIPTION (provided by applicant): It is well recognized that current batteries of genetic toxicology assays exhibit relatively high sensitivity, meaning they effectively identify genotoxic carcinogens. However, a critical deficiency with current approaches exists-namely, the specificity of the in vitro mammalian cell genotoxicity tests is low, as they yield a high incidenc of positive results t ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Enhancing Research Capacity via Developmentally Appropriate Online Data Collectio

    SBC: 3-C Institute for Social Development, Inc.            Topic: NCATS

    DESCRIPTION (provided by applicant): A central aspect of any research project is data collection, and within the clinical, behavioral, and social fields of study, data collection is traditionally carried out in-person, by telephone, or through the mail andoften involves research participants completing one or more survey questionnaires via paper-and-pencil forms. Recent technology advances have yi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. IGF::OT::IGF SBIR Topic 86 Phase I-

    SBC: Innovation Research And Training, Inc.            Topic: NHLBI

    Not Available

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. High resolution 3D dental X-ray imaging system with low dose and low cost

    SBC: XINTEK, INC.            Topic: NIDCR

    ? DESCRIPTION (provided by applicant): The need to reliably detect proximal and occlusal caries remains a high oral health priority. Caries affect millions of Americans and, when undetected, could evolve into more serious conditions that may require largerestorations, endodontic treatment, or extraction. The caries detection sensitivity using existing dental image modalities, 2D intra-oral imagin ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of NanoFludarabine for Pediatric Leukemia using LCP Nanotechnology

    SBC: QUALIBER, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Development of NanoFludarabine for Pediatric Leukemia using LCP Nanotechnology NanoFludarabine is Qualiber's nanoparticle formulation of fludarabine phosphate (Fludara), a drug widely used for treating leukemia and other malignancies. While fludarabine phosphate is effective against tumors, it also has significant toxicities. Many of these side effects can ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Eye Dropper to Improve Adherence of Glaucoma Medicine Administration

    SBC: GILERO, LLC            Topic: NEI

    Glaucoma is the leading cause of irreversible blindness worldwide and the leading cause of blindness in African Americans. Research shows that the prevalence of glaucoma is expected to increase by 50% in the next 15 years. Although medical treatment with topical eye drops can be effective at reducing the risk of blindness from the disease, many patients with glaucoma do not take their eye drops as ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a treatment for voiding dysfunction in spinal cord injured patient

    SBC: Dignify Therapeutics LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): Loss of voluntary control over bladder and bowel function as a result of spinal cord injury (SCI) has profound impact on the mental and physical health status and quality of life of patients. It is estimated that 270,000 people in the USA have SCI ((https://www.nscisc.uab.edu/PublicDocuments/fact_figures_docs/.pdf). Urinary retention as a result of SCI is irrev ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Monofunctional 3 to 10 nm Covalent Gold Labels for CryoEM

    SBC: NANOPROBES INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Gold nanoparticles are the label of choice for electron microscopy (EM) since they offer a choice of sizes that provide quantitative, high-resolution identification of targets. Recently, high-resolution EM methods including cryoEM and electron tomography have benefitted from significant advances in instrumentation and a series of breakthroughs in specimen proce ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Discovery of inhibitors of the metabolic oncogene 3-phosphoglycerate dehydrogenas

    SBC: Kadmon Corporation, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Many profound metabolic alterations have been described in solid tumors which present attractive therapeutic targets. One recently described metabolic oncogene is 3- phosphoglycerate dehydrogenase (PHGDH), the rate-limiting step in the pathway synthesizing serine and glycine for proteins, lipids, folate and nucleotide metabolism. The PHGDH gene is amplified a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government